PAM
ALDR

Paradigm Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Paradigm Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,100
Closed -$75.9K – 848
2016
Q1 		$75.9K Hold
3,100
– – 0.01% 511
2015
Q4 		$102K Buy
+3,100
New +$105K 0.02% 494

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Paradigm Asset Management's ALDR Position: Q2 2016 in Review

Paradigm Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2016, closing a stake of 3,100 shares — an estimated $75.9K sold.

Paradigm Asset Management first reported a position in ALDR in Q4 2015 and held it in 2 quarters. The position peaked at $102K in Q4 2015. 145 funds tracked by Wall St. Rank hold ALDR as of Q2 2016.

  • Paradigm Asset Management reported no remaining Alder Biopharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Paradigm Asset Management sold 3,100 Alder Biopharmaceuticals shares in Q2 2016, an estimated $75.9K.
  • Paradigm Asset Management first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Paradigm Asset Management's Alder Biopharmaceuticals position peaked at $102K in Q4 2015.
  • 145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2016.

Based on Paradigm Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.